BRAF and cutaneous melanoma: Approximately 50% of cutaneous melanomas have BRAF (V600E) mutation, and most of them respond well to BRAF inhibitor (BRAFi) treatment (vemurafenib or dabrafenib) (Chapman et al., 2011; Flaherty et al., 2010).